Abstract: The present disclosure provides an integrated system designed for the dynamic optimization of HVAC efficiency and lifestyle improvement based on real-time biomarker and environmental data. Incorporating a smart ring with biomarker sensors and an always-plugged-in environment sensing device, the system provides intelligent suggestions for HVAC settings and identifies potential causes of discomfort, enhancing comfort, health, and overall well-being.

Abstract: The present invention relates to a method and wearable device for monitoring and analyzing user movements to predict fall risk. The method involves retrieving motion data recorded by an Inertial Measurement Unit (IMU) and a pedometer, followed by processing the data once it exceeds a predefined threshold. A first trained machine learning (ML) model predicts the fall risk based on the processed data. A confidence score is determined from the fall prediction, and a second trained ML model analyzes successive data frames to confirm the fall if the score is above a threshold. If a fall is confirmed, a distress signal is transmitted. The wearable device comprises a processor and memory that stores program instructions to perform the method, including motion data retrieval, processing, fall prediction, confidence scoring, and fall confirmation, along with distress signal transmission. This invention enables timely fall detection and emergency response, improving user safety.

Abstract: The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.

Abstract: A server system for identifying test cases is provided. The server system obtains a group of test cases, each test case including a name, a description and one or more steps for testing. For each test case, the server system processes at least the description and the one or more steps using a Natural Language Processing (NLP) pre-trained model to output a vector of numerical values across n-number of dimensions. The server system compiles a group of vectors corresponding to the group of test cases. The server system applies a clustering process to the group of vectors to identify a subset of vectors from the group of vectors. The server system then outputs a subset of test cases corresponding to the subset of vectors.

Abstract: The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations).

Abstract: A system and a method for estimating size of a finger of a user. The method comprises acquiring one or more images of a hand of the user and a pre-defined reference object by an image capturing device, and recognizing the pre-defined reference object and the hand of the user, for removal of background of the one or more images. By connecting outermost points on contour of the hand, a bounding region is created by the processor. Points of convexity defects are determined on the hand for identifying each finger of the hand. A second bounding box is assigned to a finger of the hand. A size of the finger of the user is estimated based on dimension of a width of the second bounding box determined from on actual dimensions of the pre-defined reference object.

Abstract: Techniques of configuring settings for automatic update of calendar items in an electronic calendar systems are disclosed herein. In one embodiment, a server can receive and store update configuration records indicating that a change to a start date, start time, an end date, an end time, or location of a meeting would render a meeting update actionable. Upon receiving an incoming meeting update, the server can determine whether the incoming meeting update contains a change to one of a start date, start time, an end date, an end time or location. If true, the server can automatically modify, without any input from the recipient, a scheduled meeting appointment in the calendar folder of the recipient according to the received incoming meeting update.

Abstract: Methods of treating at least one cognitive symptom, e.g., at least one cognitive symptom associated with schizophrenia, comprising administering at least one compound chosen from Compound (I) and pharmaceutically acceptable salts thereof are disclosed. Also disclosed are methods of increasing D-serine levels, synaptic plasticity, and/or long-term potentiation comprising administering at least one compound chosen from Compound (I) and pharmaceutically acceptable salts thereof.

Abstract: Systems, methods, and computer program products for monitoring a health condition of a tool. Operational data is collected from a machine while the machine is operating in a predetermined manner with the tool in each of at least two known health conditions. A plurality of features is extracted from the operational data, a training dataset is generated from the extracted features, and an analytic model is trained using the training dataset. The analytic model can then be used to determine the health condition of the tool by providing features extracted from operational data received from one or more field machines to the analytic model. The analytic model may then determine a health condition of the tool in the field machine based on like features extracted from the operational data from the one or more field machines.

Abstract: The present invention is directed to pharmaceutical products, and to methods for the treatment of depression (e.g., major depressive disorder) and other diseases or disorders for which esketamine has a therapeutic benefit. In some embodiments, the methods are useful for the treatment of treatment-refractory or treatment-resistant depression or suicidal ideation. Methods of intranasal administration and devices for intranasal administration are also disclosed.

Abstract: The present invention provides methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.

Abstract: The present invention provides methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.

Abstract: The present invention provides methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.

Abstract: The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.

Abstract: Various exemplary drug delivery devices with on-board drug destruction, drug products utilizing the same, and methods of using drug delivery devices with on-board drug destruction are provided. In general, a nasal drug delivery device configured to dispense a drug therefrom into a nose includes a destruction mechanism configured to destroy drug contained in the drug delivery device. The destruction mechanism can be configured to destroy the drug before a first actuation of the drug delivery device to deliver the drug therefrom such that the destruction mechanism destroys substantially all of the drug contained in the drug delivery device. Alternatively or in addition, the destruction mechanism can be configured to destroy the drug after a first actuation of the drug delivery device to deliver the drug therefrom such that the destruction mechanism destroys substantially all of the drug remaining in the drug delivery device.

Abstract: The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.

Abstract: The present invention provides methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.

Abstract: The present invention is directed to pharmaceutical products, and to methods for the treatment of depression (e.g., major depressive disorder) and other diseases or disorders for which esketamine has a therapeutic benefit. In some embodiments, the methods are useful for the treatment of treatment-refractory or treatment-resistant depression or suicidal ideation. Methods of intranasal administration and devices for intranasal administration are also disclosed.

Abstract: The present invention is directed to methods and dosing regimens for the treatment of depression (preferably, treatment resistant depression), for the treatment of depression in a suicidal patient, and/or for the treatment and/or prevention of suicidality (e.g. suicidal ideations).

Abstract: In general, methods, systems, and devices for remote aggregation of data for drug administration devices are provided. In one exemplary embodiment, data indicative of information sensed with a sensor of a drug administration device can be wirelessly transmitted from a drug administration device to a server. The server can use the data to correlate the patients use of the drug with the patients clinical outcome, perform a cost analysis of the patients treatment, determine whether the drug was delivered to the patient in compliance with the patients treatment plan, identify a malfunction in the administration of the drug, determine that additional data is needed from the drug administration device and trigger a request for the additional data to be wirelessly transmitted from the server to the drug administration device, and/or predictively model the patients clinical outcome.